Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q1 2024 · 38 positions · Total reported value $2.10B · Top-10 concentration 63.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.0% · 6 new · 5 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2024 13F filing, Venrock Adviser, LLC disclosed 38 equity positions with a combined reported value of $2.10B. The filing implies a focused portfolio: its ten largest positions account for 63.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were APGE ($564.38M), FDMT ($140.18M), OCUL ($116.14M). By sector, the heaviest allocations are Health Care 53.0%, Industrials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+7.2pp) and away from Other (-7.1pp).

Versus the prior quarter, Venrock Adviser, LLC opened 6 new positions, trimmed 5 and fully exited 5, a turnover rate of 41.0% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q1 2024 were ENGN ($43.49M), EWTX ($33.16M), AQST ($23.67M).

Of the 5 positions fully exited versus the prior quarter, the largest were RYZB ($250.57M), AMAM ($29.48M), RYTM ($22.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • ENGN ENGENE THERAPEUTICS INC · $43.49M
  • EWTX EDGEWISE THERAPEUTICS INC · $33.16M
  • AQST AQUESTIVE THERAPEUTICS INC · $23.67M
  • IMTX Immatics NV · $18.39M
  • CGON CG ONCOLOGY INC · $15.37M
  • IPSC CENTURY THERAPEUTICS INC · $14.23M
  • TNYA TENAYA THERAPEUTICS INC · $8.14M
  • MLYS MINERALYS THERAPEUTICS INC · $7.17M

Fully Exited (vs previous quarter)

  • RYZB RAYZEBIO INC · prev qtr: $250.57M
  • AMAM AMBRX BIOPHARMA INC · prev qtr: $29.48M
  • RYTM RHYTHM PHARMACEUTICALS INC · prev qtr: $22.80M
  • SVRA SAVARA INC · prev qtr: $16.45M · history
  • GHRS GH RESEARCH PLC · prev qtr: $7.65M
  • MIST MILESTONE PHARMACEUTICALS IN · prev qtr: $1.54M

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 34 US equity positions with a combined value of $2.06B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 34 positions · $2.06B reported value (Q3 2026)
  • Top 10 holdings = 71.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 16.8%
  • Average position size: $60.54M

Sector Tilt

  • Health Care 99.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 6 added, 5 reduced, 5 exited
  • 17 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 53.0%
Other 46.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 8.49M $564.38M 26.85%
26.85%
Hold
2 4.40M $140.18M 6.67%
6.67%
Add
3 12.76M $116.14M 5.53%
5.53%
Add
4 2.17M $82.38M 3.92%
3.92%
Reduce
5 1.79M $80.61M 3.83%
3.83%
Reduce
6 3.40M $78.47M 3.73%
3.73%
Hold
7 6.25M $74.12M 3.53%
3.53%
Add
8 4.03M $70.82M 3.37%
3.37%
Add
9 3.88M $67.99M 3.23%
3.23%
Hold
10 2.09M $62.83M 2.99%
2.99%
Add
11 2.17M $61.72M 2.94%
2.94%
Hold
12 9.07M $61.71M 2.94%
2.94%
Add
13 4.39M $60.42M 2.87%
2.87%
Add
14 3.61M $50.79M 2.42%
2.42%
Add
15 11.33M $50.75M 2.41%
2.41%
Hold
16 2.57M $43.49M 2.07%
2.07%
New
17 706.13K $43.09M 2.05%
2.05%
Add
18 2.08M $34.51M 1.64%
1.64%
Hold
19 5.13M $34.47M 1.64%
1.64%
Add
20 1.82M $33.16M 1.58%
1.58%
New
21 1.56M $26.68M 1.27%
1.27%
Reduce
22 627.79K $25.92M 1.23%
1.23%
Hold
23 9.00M $25.83M 1.23%
1.23%
Reduce
24 5.56M $23.67M 1.13%
1.13%
New
25 3.41M $22.37M 1.06%
1.06%
Reduce
26 1.56M $22.01M 1.05%
1.05%
Reduce
27 970.00K $20.95M 1.00%
1.00%
Reduce
28 1.35M $19.24M 0.92%
0.92%
Add
29 1.75M $18.39M 0.88%
0.88%
New
30 2.58M $16.02M 0.76%
0.76%
Hold
31 350.00K $15.37M 0.73%
0.73%
New
32 3.41M $14.23M 0.68%
0.68%
New
33 3.42M $11.81M 0.56%
0.56%
Hold
34 1.56M $8.14M 0.39%
0.39%
New
35 555.55K $7.17M 0.34%
0.34%
New
36 937.11K $6.33M 0.30%
0.30%
Hold
37 250.00K $5.17M 0.25%
0.25%
Hold
38 77.04K $872.12K 0.04%
0.04%
Hold

FAQ

What did Venrock Adviser, LLC buy in 2024-Q1?

In its 2024-Q1 13F filing, Venrock Adviser, LLC reported 38 equity positions worth $2.10B in aggregate; its largest disclosed positions were APGE ($564.38M), FDMT ($140.18M), OCUL ($116.14M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $2.10B of long equity holdings across 38 positions as of 2024-Q1. Top-10 holdings account for 63.6% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →